Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 20 years at the time of signing the informed consent document~* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted~* Able to adhere to the study visit schedule and other protocol requirements~* Previously untreated, symptomatic multiple myeloma~* Have measurable disease by protein electrophoresis analyses~* At least 65 years of age or older or, if younger than 65 years of age, not candidates for hematopoietic stem cell transplantation~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan~Exclusion Criteria:~* Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study~* Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~* Any condition that confounds the ability to interpret data from the study~* Previous treatment with anti-myeloma therapy~* Pregnant or lactating females~* Any of the following laboratory abnormalities:~  * Absolute neutrophil count (ANC) \< 1,000/microL (1.0 × 10\^9/L )~ * Untransfused platelet count (a platelet count drawn at least 7 days after the administration of the last platelet transfusion) \< 50,000 cells/microL (50 × 10\^9/L)~ * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3.0 × upper limit of normal~* Renal failure requiring hemodialysis or peritoneal dialysis~* Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years~* Subjects who are unable or unwilling to undergo antithrombotic therapy.~* Peripheral neuropathy of ≥ grade 2 severity.~* Uncontrolled systemic fungal, bacterial, or viral infection~* Known human immunodeficiency virus (HIV) positivity (subjects who are receiving antiretroviral therapy for HIV disease)~* Hepatitis Bs (HBs) antigen-positive, or hepatitis C virus (HCV) antibody-positive. In case HBc antibody and/or HBs antibody is positive even if HBs antigen-negative, a Hepatitis B virus (HBV) DNA test should be performed and if positive the subject will be excluded.~* Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis.~* Ineligible for dexamethasone or dexamethasone is contraindicated.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide plus dexamethasone (Type: EXPERIMENTAL): Lenalidomide plus low-dose dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).